TECENTRIQ + AVASTIN®


(bevacizumab)


A STRONG FIRST STEP FOR YOUR PATIENTS


WITH UNRESECTABLE OR METASTATIC HCC


After over a decade, the standard of care in 1L unresectable or metastatic HCC has evolved past sorafenib.1,2


Atezolizumab (TECENTRIQ) + bevacizumab (Avastin) is currently the only Category 1, preferred first-line systemic therapy option recommended by the NCCN Guidelines®


in unresectable* or metastatic HCC.


CATEGORY 1, PREFERRED OPTION


NCCN


Atezolizumab (TECENTRIQ) + bevacizumab (Avastin) is the only Category 1, preferred fi rst-line systemic therapy option for patients with unresectable* or metastatic hepatocellular carcinoma (Child-Pugh Class A) in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®


).3†‡§


*In patients who are not transplant candidates. †


‡


NCCN makes no warranties of any kind whatsoever regarding their content, use, or application, and disclaims any responsibility for their application or use in any way. See the NCCN Guidelines®


for detailed recommendations. §


Category 1: based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate.


Preferred intervention: interventions that are based on superior efficacy, safety, and evidence; and, when appropriate, affordability.


Indication TECENTRIQ, in combination with bevacizumab, is indicated for the treatment of patients with unresectable or metastatic hepatocellular carcinoma (HCC) who have not received prior systemic therapy.


Important Safety Information


Severe and Fatal Immune-Mediated Adverse Reactions TECENTRIQ is a monoclonal antibody that belongs to a class of drugs that bind to either the programmed death-receptor 1 (PD-1) or the PD-ligand 1 (PD-L1), blocking the PD-1/PD-L1 pathway, thereby removing inhibition of the immune response, potentially breaking peripheral tolerance and inducing immune-mediated adverse reactions. The following immune- mediated adverse reactions may not include all possible severe and fatal immune-mediated reactions.


Immune-mediated adverse reactions can occur in any organ system or tissue and at any time after starting TECENTRIQ. While immune-mediated adverse reactions usually manifest during treatment with TECENTRIQ, they can also manifest after discontinuation of treatment. Early identifi cation and management of immune-mediated adverse reactions are essential to ensure safe use of TECENTRIQ.


Monitor patients closely for symptoms and signs that may be clinical manifestations of underlying immune-mediated adverse reactions. Evaluate liver enzymes, creatinine, and thyroid function at baseline and periodically during treatment. In cases of suspected immune-mediated adverse reactions, initiate appropriate workup to exclude alternative etiologies, including infection. Institute medical management promptly, including specialty consultation as appropriate.


Withhold or permanently discontinue TECENTRIQ depending on severity. In general, if TECENTRIQ requires interruption or discontinuation, administer systemic corticosteroid therapy (1 to 2 mg/kg/day prednisone or equivalent) until improvement to Grade 1 or less, then initiate corticosteroid taper and continue to taper over at least 1 month. Consider administration of other systemic immunosuppressants in patients whose immune-mediated adverse reactions are not controlled with corticosteroid therapy.


Immune-Mediated Pneumonitis • TECENTRIQ can cause immune-mediated pneumonitis. The incidence of pneumonitis is higher in patients who have received prior thoracic radiation


Please see additional Important Safety Information and Brief Summary of Prescribing Information on the following pages.


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48